Skip to main content

Table 1 Baseline data: “On-diet”: 36 pregnancies in patients who followed a supplemented vegan diet in pregnancy (31 singleton deliveries)

From: Vegan-vegetarian low-protein supplemented diets in pregnant CKD patients: fifteen years of experience

Case Age (yrs) Pre-conceptional; Referral-week Kidney disease sCr mg/dL (EPI-GFR mL/min) CKD stage PtU (g/24 h) Pt/Alb (g/dL) HT Therapy at referral BMI
1 35 pre; ICSI Diab neph 1.2 (59) 3 2.5 5.9/2.8 Yes Insulin, doxazosine 23.5
2 35 pre; 8w Diab neph 1.6 (45) 4 1.8 6.5/3.8 No Insulin 22
3 28 7w Sponge kidney 3.2 (19) 4 0.8 6.5/3.5 No EPO, Vit. D 22
4 37 pre; 6w Diab neph 1.2 (58) 3 5.9 5.8/3.2 No Insulin 22
5 32 6w SLE 0.7 (115) 1 2.7 6.0/3.1 Yes Pred., ASA, omeprazole, a-MD 24
6 35 pre; 7w Reflux 3.2 (18) 4 1.0 8.4/4.5 Yes Vit. D, b-blocker ASA 19
7 29 9w Diab neph 1.5 (47) 3 6.3 6.6/3.6 Yes Insulin, nifedipine 20
8 38 17w fibrillary GN 0.6 (116) 1 3.6 5.8/2.6 No None 22
9 32 6w Kidney graft 1.2 (60) 2 0.5 6.9/4.0 No Pred., CyA, ranitidine, ASA, 24
10 20 5w SLE 0.6 (132) 1 2.5 6.8/3.3 No Pred. 21
11 37 7w Kidney graft 1.5 (44) 3 0.8 7.0/3.9 Yes Pred., CyA, VitD, nifedipine, ASA EPO, ranitidine 27
12 30 6w IgA GN 1.3 (55) 3 0.7 6.9/4.1 No Levothyroxine 18.9
13 28 10w IgA GN 1 (77) 2 2 6.6/3.7 No None 19.9
14 36 pre; 5w Diab neph 1 (68) 2 0.6 6.4/4.1 Yes Lansoprazole, levothyroxine, ASA, Niphedipine, insulin, 21.5
15 35 7w Diab neph 1.2 (56) 3 0.7 7.4/4.3 No Insulin 18.2
16 40 24w Diab neph 0.9 (76) 2 3.1 6.7/3.3 Yes Insulin, levothyroxine, Nifedipine 24
17 36 20w IgA GN 1.1 (64) 2 2.4 5.6/4.1 No None 22.3
18 36 pre; 7w SLE 2.9 (20) 4 3.4 6.5/3.9 Yes Pred., levothyroxine, a-MD 24.5
19 38 6w FSGS 0.6 (116) 1 2.1 6.3/3.3 No CyA 25
20 33 pre; 8w Kidney graft 1.3 (52) 3 0.2 7.2/3.9 Yes Pred, TAC 30
21 31 pre; 9w Sponge kidney 1.6 (43.3) 3 0.3 6.5/4.0 Yes ASA, a-MD 23.4
22 33 pre; 7w Reflux 0.7 (110.4) 1 0.8 6.0/3.7 Yes ASA, b-bloc 21.8
23 38 pre; 6w Pyelonephritis 1.2 (59) 3 0.2 6.5/3.9 Yes a-MD 19.7
24 26 5w Single kidney, previous HUS 1 (78) 2 0.3 6.8/3.8 Yes ASA 23.4
25 41 pre; 7w GN 0.8 (86.6) 2 0.8 7.2/3.8 Yes ASA 33.6
26 32 6w IgA GN 1 (74.7) 2 0.6 6.8 /3.9 No ASA 24.9
27 36 18w Diab neph 0.7 (106.3) 1 0.9 7.4/4.4 Yes ASA, a-MD, Insulin 34
28 33 27w LLAC 0.4 (136.2) 1 1.3 6.0/3.6 Yes a-MD 29.7
29 33 14w Unknown 0.8 (105.6) 1 2.2 5.7/3.0 No ASA 24.8
30 32 30w Unknown 1.7 (39.6) 3 0.1 6.2/3.6 No / 26.7
31 31 8 w Diab neph 1.48 (47) 3 0.1 6.78/4.68 No ASA, Insulin 19.5
32 (twin) 31 21w Diab neph 0.5 (128) 1 5.4 5.5/2.8 No Insulin, levothyroxine 17.9
33 (twin) 37 12w Unknown 0.7 (112) 1 0.8 7.1/3.5 No None 31.4
34 (twin) 39 11 w Previous PNA 0.57 (184.1) 1 0.29 6.11/3.37 No ASA 32.32
35 (termination) 26 18w MGN 0.6 (126) 1 5.5 5.1/2.3 No None 19
36 (miscarriage) 37 7w Kidney graft 1.7 (38) 3 0.1 6.9/3.9 Yes Pred., TAC, EPO, ASA, omeprazole, Doxazosin, b-bloc 25.1
Summary data all cases
Median (min-max)
34 (20–41) 7 (5–30) _ sCr
1.05 (0.4–3.2)
GFR-EPI
66.0 (18.0–184.1)
2 (1–4) 0.8 (0.1–6.3) Pt
6.5 (5.1–8.4)
Alb
3.75 (2.3–4.68)
17/36
47.2 %
_ 23.4 (17.9–34.0)
Summary data
Singletons
Median (min-max)
33
(20–41)
7 (5–30) _ sCr
1.20 (0.4–3.2)
GFR-EPI
60.0 (18.0–136.2)
3 (1–4) 0.9 (0.1–6.3) Pt
6.5 (5.6–8.4)
Alb
3.8 (2.6–4.68)
16/31
51.6 %
_ 23.4 (18.2–34.0)
  1. Data at referral: data observed at the first follow-up in our unit
  2. HT hypertension, SLE systemic lupus erythematosus, IgA GN IgA nephropathy, FSGS focal segmental glomerlosclerosis, Diab Neph diabetic nephropathy, BMI body mass index, PtU 24 hour proteinuria, sCr serum creatinine, GFR glomerular filtration rate, SLE systemic lupus erythematosus. CyA cyclosporine A, ASA acetyl salicylic acid, Pred. prednisone, TAC tacrolimus, EPO erythropoietin, B-Bloc beta blocker, a-MD alpha methyldopa, ICSI intracytoplasmatic sperm injection